INSM Insmed Incorporated
Insmed Incorporated (INSM) is expected to report earnings on November 5, 2026, before the market open. The consensus earnings estimate is a loss of $0.37 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -3.5% since its last earnings release on August 6, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Insmed Incorporated
Insmed Inc is a biopharmaceutical company engaged in developing and commercializing inhaled therapies for patients battling serious lung diseases that are often life threatening. Its products candidates includes ARIKAYCE.
Sector
Healthcare
Industry
Biotechnology